Heart failure (HF) continues to be a major health problem and is an end-point of cardiac injury, which in many cases is preceded by cardiac hypertrophy and adverse remodeling. We have found that G protein-coupled receptor (GPCR) signaling and regulation of this signaling by GPCR kinases (GRKs) play crucial roles in the pathological processes of maladaptive cardiac hypertrophy and ventricular remodeling. GRK2 and GRKS are the major cardiac GRKs and both have been found to be up-regulated in failing human myocardium so their function in the injured heart is of significance. In the first funding cycle of this Project, we have identified that GRKS plays a novel non-GRK role in cardiomyocyte signaling and function within the nucleus of myocytes acting as a Class II histone deacetylase (HDAC) kinase. This HDAC kinase activity of GRKS can facilitate maladaptive cardiac hypertrophy and accelerate HF development. We now have new preliminary data to suggest there are additional targets within the myocyte for GRKS, including in the nucleus, that can promote myocyte dysfunction. Included is the nuclear factor of activated T-cell (NFAT) pathway and it appears that GRKS can activate this critical molecule in the heart. We will also investigate the role of GRKS in ischemic injury and repair and have assembled several key mouse models and viral constructs to delineate specific pathological and therapeutic mechanisms surrounding this kinase. Included is the development of a novel knock-in mouse where all endogenous GRKS will be defective in its ability to enter the nucleus. Using these we will test the Central Hypothesis that GRKS plays a critical (patho)- physiological role in the cardiomyocyte's response to injury and targeting and manipulating its unique cellular localization and activity is a novel therapeutic strategy for preventing maladaptive cardiac hypertrophy, ventricular remodeling and HF. Our associated Specific Aims to test this hypothesis are: [1] To determine the mechanisms involved in the GRKS-mediated regulation of cardiac NFAT signaling; [2] To determine the mechanistic role of nuclear GRKS activity in the heart's response to ischemic injury; and [3] To determine the ultimate physiological role for nuclear GRKS activity and localization in cardiac injury and repair.

Public Health Relevance

Heart failure (HF) is a major health problem throughout the world and understanding molecular processes involved in cardiac injury and repair can advance development of novel therapies. We have found that a specific kinase, GRKS, can play a key role in HF pathogenesis and through continued GRKS-targeted research in this area can lead to translatable strategies to combat cardiac injury HF.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL091799-10
Application #
9475276
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Schwartz, Lisa
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Temple University
Department
Type
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
de Lucia, Claudio; Gambino, Giuseppina; Petraglia, Laura et al. (2018) Long-Term Caloric Restriction Improves Cardiac Function, Remodeling, Adrenergic Responsiveness, and Sympathetic Innervation in a Model of Postischemic Heart Failure. Circ Heart Fail 11:e004153
Tahrir, Farzaneh G; Shanmughapriya, Santhanam; Ahooyi, Taha Mohseni et al. (2018) Dysregulation of mitochondrial bioenergetics and quality control by HIV-1 Tat in cardiomyocytes. J Cell Physiol 233:748-758
Myers, Valerie D; McClung, Joseph M; Wang, JuFang et al. (2018) The Multifunctional Protein BAG3: A Novel Therapeutic Target in Cardiovascular Disease. JACC Basic Transl Sci 3:122-131
Myers, Valerie D; Tomar, Dhanendra; Madesh, Muniswamy et al. (2018) Haplo-insufficiency of Bcl2-associated athanogene 3 in mice results in progressive left ventricular dysfunction, ?-adrenergic insensitivity, and increased apoptosis. J Cell Physiol 233:6319-6326
Borghetti, Giulia; von Lewinski, Dirk; Eaton, Deborah M et al. (2018) Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol 9:1514
Grisanti, Laurel A; Schumacher, Sarah M; Tilley, Douglas G et al. (2018) Designer Approaches for G Protein-Coupled Receptor Modulation for Cardiovascular Disease. JACC Basic Transl Sci 3:550-562
de Lucia, Claudio; Eguchi, Akito; Koch, Walter J (2018) New Insights in Cardiac ?-Adrenergic Signaling During Heart Failure and Aging. Front Pharmacol 9:904
Grisanti, Laurel A; Thomas, Toby P; Carter, Rhonda L et al. (2018) Pepducin-mediated cardioprotection via ?-arrestin-biased ?2-adrenergic receptor-specific signaling. Theranostics 8:4664-4678
Cannavo, Alessandro; Koch, Walter J (2018) GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease. Cell Signal 41:33-40
Yeh, Szu-Tsen; Zambrano, Cristina M; Koch, Walter J et al. (2018) PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) regulates G-protein-coupled receptor kinase 5 (GRK5)-induced cardiac hypertrophy in vitro. J Biol Chem 293:8056-8064

Showing the most recent 10 out of 163 publications